Oncocyte (OCX) | Stock Overview & Key Data
Oncocyte Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $204.80 on January 4, 2016
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Mar 31, 2025
Annual Income Flow
2024
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Oncocyte
OCX
|
65.62M Micro-cap | -5.93% | 15.30% | 10.64% | 12.92% | -15.78% | 87.05% | 41.14% | -93.86% | -92.52% | -95.03% | -95.03% |
|
Thermo Fisher
TMO
|
174.55B Large-cap | 3.89% | 2.45% | -6.72% | -18.35% | -20.01% | 22.27% | -5.31% | 9.75% | 222.18% | 684.25% | 1,233.99% |
|
Danaher
DHR
|
126.39B Large-cap | 2.86% | 2.32% | -12.71% | -22.05% | -22.71% | -3.81% | -12.18% | -14.95% | 176.52% | 423.71% | 744.91% |
| 221.68M Micro-cap | -28.59% | -49.45% | -63.08% | -61.80% | -55.84% | 200.65% | 285.12% | -65.34% | -62.16% | -62.16% | -62.16% | |
|
Fonar
FONR
|
118.64M Micro-cap | 0.95% | 0.90% | 2.86% | 32.66% | 3.08% | 31.72% | 13.49% | 5.18% | 16.25% | 827.18% | 55.92% |
|
Biodesix
BDSX
|
107.54M Micro-cap | 8.71% | 42.86% | 3.87% | 97.79% | 149.23% | 170.20% | -39.56% | -94.00% | -93.44% | -93.44% | -93.44% |
Ownership & Short Interest
Calculate Your Oncocyte Investment Returns
Long-Term Investment Performance Analysis
Oncocyte stock price in May 2016 was $83.00, A $1,000.00 lump sum investment in Oncocyte made 10 years ago would be worth approximately $72.65 today, representing a negative return of -92.73%. This translates to an annualized return (CAGR) of -23.05%.
10 Years Investment Scenario (May 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is OCX's 52-week high and low?
- In the last 52 weeks, Oncocyte reached a high of $8.51 (on November 12, 2025) and a low of $2.33 (on August 29, 2025).
- What is the market cap and P/E ratio for OCX?
- Curious about Oncocyte's size and valuation? Its market capitalization stands at 65.62M. When it comes to valuation, the P/E ratio (trailing twelve months) is -0.81, and the forward P/E (looking ahead) is -1.85.
- Does OCX pay dividends? If so, what's the yield?
- As for dividends, Oncocyte isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Oncocyte's main competitors or similar companies to consider before investing?
When looking at Oncocyte, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Thermo Fisher
TMO174.55B Healthcare Diagnostics & Research 22.27% -5.31% Danaher
DHR126.39B Healthcare Diagnostics & Research -3.81% -12.18% Burning Rock Biotech
BNR221.68M Healthcare Diagnostics & Research 200.65% 285.12% Fonar
FONR118.64M Healthcare Diagnostics & Research 31.72% 13.49% Biodesix
BDSX107.54M Healthcare Diagnostics & Research 170.20% -39.56% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Oncocyte Corporation? (e.g., ROE, Debt/Equity)
- To get a sense of Oncocyte's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 496.38%, the Debt to Equity ratio from the most recent quarter is 3.07, and its Gross Profit Margin stands at 67.57%.
- What is the recent revenue and earnings growth for OCX?
- Looking at Oncocyte's growth, its revenue over the trailing twelve months (TTM) was $2M. Compared to the same quarter last year (YoY), quarterly revenue grew by -75.77%, and quarterly earnings saw a YoY growth of N/A.
- How much of OCX stock is held by insiders and institutions?
- Wondering who owns Oncocyte stock? Company insiders (like executives and directors) hold about N/A of the shares, while institutional investors (such as mutual funds and pension funds) own approximately N/A.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.